Business Wire

Tech Recruitment Goliath to Open Its First Office in Switzerland

12.1.2021 18:00:00 EET | Business Wire | Press release

Share

UK staffing firm Frank Recruitment Group has today announced the opening of its latest location in Geneva, Switzerland.

The new office is the cloud recruitment company's eighth in Europe, bringing its total number of global hubs to 21.

Frank Recruitment Group, founded in Newcastle upon Tyne in 2006 with just three members of staff, now employs almost 2,000 people worldwide and is part of Tenth Revolution Group, the global leader in cloud talent solutions. The Swiss location will add a number of new team members to that headcount, with plans to create up to 50 jobs within five years.

The move will see Frank Recruitment Group further increase its reach in Europe and enable the firm to better support its growing global client base.

With the country's technology market expanding fast, and digitalisation and cloud migration at the top of every Swiss CIO's agenda, demand for IT professionals to support transformation is mounting.

"Our new Swiss base will allow us to offer better support to our clients and partners in the region, at a time when specialist technology recruitment consulting is more needed than ever," said Director of Sales Paul Hanley, who will be leading the new location.

"We want to replicate the success we’ve achieved in other global regions here in Switzerland by solidifying our position as the leaders in cloud tech staffing solutions, and continue to enable digital transformation by delivering the best permanent and contract tech talent to businesses that need it," Hanley said.

"I'm especially proud to be launching our Swiss office," said Zoë Morris, Frank Recruitment Group President. "2020 was a challenging year for the staffing industry, so it feels like a special achievement to be opening a new location and growing our business at this time. We feel very privileged to be able to serve this exciting market and create new jobs in the area in the process."

Hanley added, "Our launch team is packed with seasoned, multi-lingual staffing experts, all of whom have significant experience within the Swiss recruitment industry. Our focus is entirely on the tech market, and that will allow us to deliver the kind of dedicated, specialist expertise that's been missing in the Swiss market so far. I'm incredibly excited to get to work in the market, and make a real impact for both businesses and tech professionals in the area by connecting the right people with the right jobs."

At the new location, Frank Recruitment Group will initially launch its Nigel Frank, Mason Frank, and FRG Technology Consulting brands, which recruit for Microsoft, Salesforce, and emerging technology specialists, respectively.

The Swiss office is based at 14 Rue du Rhône, Geneva.

Note to editors:

ABOUT FRANK RECRUITMENT GROUP

Frank Recruitment Group is a division of Tenth Revolution Group, the world’s leading experts in cloud talent solutions. Founded in Newcastle upon Tyne, in 2006, Frank Recruitment Group creates and delivers highly sought-after professionals in some of the industry’s most skills-scarce ecosystems.

The company employs nearly 2,000 people across 20 offices, including Dallas, New York, Philadelphia, San Francisco, Tampa, Denver, Scottsdale, Charlotte, and Irvine in the US. EMEA and APAC are served by nine offices across the UK, Germany, the Netherlands, Spain, and locations in Singapore and Australia.

The group operates seven trading brands that each focus on a specific technology product: Jefferson Frank (AWS), Nigel Frank International (Microsoft Dynamics and Azure), Mason Frank International (Salesforce), Washington Frank (enterprise ERP), Anderson Frank (NetSuite), Nelson Frank (ServiceNow), and FRG Technology Consulting (Marketing Automation and emerging technologies).

Frank Recruitment Group was named one of Europe’s fastest-growing companies and received recognition as one of the UK’s top 100 private companies with the fastest-growing profits. The group plans to expand its outreach globally and attract more trainee recruiters in strategic hubs to meet demand for its services.

For more information, visit: www.frankgroup.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiries:
Josie Middleton
T: +44 (0)191 338 7553
E: j.middleton@frankgroup.com
W: www.frankgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye